OneOncology's 26 Pathways Only
5th Program to Receive ASCO Certification
NASHVILLE, Tenn., May 21, 2024
/PRNewswire/ -- OneOncology, the fastest-growing national
platform for independent practices, announced that the ASCO
Certified Task Force has approved OneOncology Treatment Pathways as
appropriate for use in ASCO Certified. OneOncology's 26 unique
oncology and hematology pathways are only the fifth available
pathway program reviewed and determined appropriate for use in this
prestigious certification program.
OneOncology's 26 Pathways Only 5th Program
to Receive ASCO Certification
"ASCO's stamp of approval of our treatment pathway program is a
validation of our clinical team's rigorous work to develop pathways
that efficiently put the latest medical evidence into the hands of
all of our physician partners and streamline their ordering
process," said Davey Daniel, MD,
OneOncology's Chief Medical Officer. "OneOncology's pathways, which
are concordant with many nationally recognized evidence-based
guidelines, list various treatment options ensuring they are
all-encompassing and include clinical trials when available for a
specific cancer setting."
OneOncology takes a physician-led approach to pathway
development. Edward Arrowsmith, MD,
Medical Director of OneOncology's Pathways Program, and physician
experts from its five disease groups (gastrointestinal,
genitourinary, breast, lung, and hematology) and other disease
subject matter physician experts (gynecology, head, and neck) lead
in authoring OneOncology pathways, which are published inside
OneOncology's clinical decision support tool utilized by its
partner practices.
Developing pathways begins with the Pharmacy and Therapeutics
(P&T) Committee of an all-physician body called OneCouncil that
reviews and approves all new indications or new molecular entities,
and then authors a drug monograph. Once the monograph has been
approved by the P&T Committee, the newly-approved agent is
incorporated in draft form into the appropriate pathway and
presented to the appropriate OneCouncil Disease Group. Based on
efficacy and the adverse event profile of the new agent compared
with other treatment options, Disease Group members decide if and
where it should be added to the pathway.
Pathways are reviewed and updated regularly by OneOncology
experts when data is presented at nationally recognized meetings or
in peer-reviewed journals. Each pathway is broken out by
appropriate stage and treatment options by stage, including
neoadjuvant, adjuvant, recurrent, locally advanced, and metastatic
treatment settings, and have potential treatment options clearly
listed.
"Our treatment pathways increase appropriate first-line
treatment, based on genomic testing and biomarkers, while reducing
adverse events experienced by patients due to standardized regimens
and appropriate supportive care," said Lisa
Raff, OneOncology's Vice President of Pharmacy Services.
"Being recognized by ASCO Certified demonstrates to our physician
partners the OneOncology Treatment Pathways meet ASCO Criteria
for High Quality Clinical Pathways in Oncology."
About OneOncology
OneOncology was founded by
community oncologists, for community oncologists, with the mission
of improving the lives of everyone living with cancer. Our goal is
to enable community oncology practices to remain independent and to
improve patient access to care in their communities, all at a lower
cost than in the hospital setting. OneOncology supports our
platform of community oncology practices through group purchasing,
operational optimization, data analytics, practice growth, and
clinical innovation. Our 1,100 cancer care providers care for
approximately 750,000 patients at more than 400 sites of care
nationwide. To learn more,
visit oneoncology.com or LinkedIn.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/oneoncologys-treatment-pathways-certified-by-asco-302150748.html
SOURCE OneOncology, LLC.